 CAMBRIDGE, Mass., May 10, 2021 GLOBE NEWSWIRE -- Checkmate Pharmaceuticals, Inc. NASDAQ: CMPI Checkmate, a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the development program expansion of vidutolimod CMP-001 into non-melanoma skin cancers in combination with Libtayo cemiplimab under a clinical supply agreement with Regeneron Pharmaceuticals, Inc. Regeneron. Vidutolimod is an advanced generation Toll-like receptor 9 TLR9 agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component. Cemiplimab is a PD-1 blocking antibody being jointly developed by Regeneron and Sanofi. 